By Dean Seal
DBV Technologies' American depositary receipts fell after the company said its cash would likely run out after next month.
The stock was down 10% at $4.48 in premarket trading on Monday. Shares had gained 61% year-to-date through Friday's close, though they were trading up at $7.96 this time a year ago.
The clinical-stage biopharmaceutical company disclosed overnight that it has substantial doubt about its ability to continue as a going concern.
DBV said it has incurred operating losses and negative cash flows from operations since the company started, and that there currently isn't enough available cash and cash equivalents to support its operating plan for the next 12 months.
The company expects that its current cash load would only be enough to fund operations into April. DBV is seeking additional capital for R&D efforts, but can't guarantee that it will get enough financing to meet its needs, or financing with attractive terms and conditions.
DBV said it may have to scale back operations, delay or reduce its R&D efforts or relinquish rights to its product candidates if it can't meet its financing goals.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
March 24, 2025 08:11 ET (12:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。